In this study, investigators from Sweden evaluated inflammatory biomarkers in plasma and in circulating monocytes obtained from patients with Crohn's disease and healthy individuals.
The team also assessed the effects of atorvastatin, 10 µM, ex vivo on monocytes cultured for 18 hours from the same subjects.
The team analyzed plasma and blood monocytes from 8 patients with active Crohn's disease and 8 healthy controls using enzyme-linked immunosorbent and electrophoretic mobility assays.
The investigators found that the Crohn's patients had increased plasma levels of tumor necrosis factor (TNF)-alpha, monocyte chemo-attractant protein (MCP)-1, and oxidized low density lipoprotein (oxLDL).
Furthermore, monocytes from these patients showed enhanced secretion of MCP-1 and suppressed secretion of macrophage migration inhibitory factor (MIF).
The team found that treating monocytes with atorvastatin resulted in the suppression of MCP-1 and TNF-α secretion.
Dr Olof Grip and colleagues concluded, "These results show increased levels of certain proinflammatory bio-markers, including oxLDL, in plasma and indicate that peripheral blood monocytes in active Crohn's disease are sensitized to chemotaxis".
"Treatment with atorvastatin may be a potential strategy to reduce oxLDL and inhibit monocyte migration to inflamed tissue, thus attenuating the inflammatory response".